Tag:
patent expirations
Latest Headlines
Latest Headlines
FDA halts generic OxyContin, handing Purdue a victory
For months FDA regulators have been wrestling with the dangers of allowing a flood of cheap, generic version of the highly addictive OxyContin on the market vs. consumers with pain issues having access to cheaper meds.
Forget $4 generics. Free Lipitor copies are the new drug promo
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.
UPDATED: Loss of Actos weighs heavily on Takeda
Takeda Pharmaceutical last week nailed down FDA approval for three new diabetes drugs--DPP-4 inhibitors--and it was none too soon, as today's earnings report makes crystal clear.
Forest's Lexapro plague lingers with 41% hit to Q3 sales
Forest Laboratories is in dire need of a Bloody Mary for its still-severe Lexapro hangover. The U.S.-based drugmaker fell short of low expectations for the third quarter, thanks to a 41% drop in sales, largely because of generic competition for the blockbuster antidepressant. And the company ratcheted back predictions for its full-year results.
U.S. branded sales to end 2012 with 3.5% decline
By the time the ball drops in Times Square this year, branded drug sales will have dropped 3.5%. So says a new report on U.S. spending, which pegs this year's decline at that rate--and forecasts an annual decline of 2.6%, on average, over the next several years.
Top 15 drug patent losses for 2013
We are in the midst of third quarter earnings reports, and they show with stark detail what the tsunami of patent losses means to the financial underpinning of drugmakers. It's a serious problem that will erode earnings for years to come. Pharmaceutical researcher EvaluatePharma estimates there are $290 billion of sales at risk from patent expirations between this year and 2018. Read the full report >>
Fitch flags big obstacles ahead for Eli Lilly
The credit-analysis firm confirmed the drugmaker's current ratings, but changed its outlook to "negative" from "stable." That's because Lilly is walking toward two big patent expirations, fresh off its recent loss of Zyprexa exclusivity.
Generic savings tell a different patent-loss tale
Earnings season has provided one measure of how hard patent losses and generic competition have hit pharma companies. The thousands and thousands of laid off workers is another gauge. But a new IMS study provides a fascinating picture of how much U.S. drug buyers, including the government, have saved.
U.K. drug spending down, scripts up on 'patent dividend'
Want a statistical representation of the patent cliff's decidedly mixed blessings? The U.K. just released its latest report on drug spending. The gist is, costs are down but prescription numbers are up. And that's because more patients are using cheap generics as branded drugs go off patent.
Beware: Patent losses to climb back to $56B by 2015
As EvaluatePharma reminds us in its latest World Preview report, 2012 is far from the end of pharma's patent woes.
